Immunogen (IMGN) Tops Q4 EPS by 4c, FY Revenue Guidance Misses

Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $12.27 million.

GUIDANCE:

Immunogen sees FY2019 revenue of $40-45 million, versus the consensus of $84.56 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04